<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37506137</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2050-4527</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Immunity, inflammation and disease</Title><ISOAbbreviation>Immun Inflamm Dis</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta-analysis and a propensity score-matched case-control study.</ArticleTitle><Pagination><StartPage>e954</StartPage><MedlinePgn>e954</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e954</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/iid3.954</ELocationID><Abstract><AbstractText Label="OBJECTIVE">In this study, we performed a meta-analysis and a propensity score-matched case-control study to evaluate the efficacy and safety of belimumab in patients with lupus nephritis&#xa0;(LN).</AbstractText><AbstractText Label="METHODS">We analyzed the data from three randomized controlled trials (RCTs) to assess the effects of belimumab treatment on renal improvement and adverse effects. Our study included a total of six LN patients who received belimumab treatment&#xa0;and an additional six LN patients who received standard therapy. All participants were followed up for a duration exceeding 96 weeks to evaluate the outcomes of the treatments.</AbstractText><AbstractText Label="RESULTS">Our meta-analysis incorporated data from three articles involving a total of 666 patients. The results of the analysis revealed that a higher proportion of patients who received belimumab treatment experienced renal improvement compared to those in the control group. The patients in belimumab group had a higher renal complete response rate and proteinuria improvement rate compared to the control group. However, belimumab treatment did not increase the renal partial response rate compared to the control group. The belimumab group also exhibited a higher proportion of patients who achieved normalization of antidouble-stranded DNA, as well as normalization of low C3&#xa0;and C4 levels. In our case-control study, significant improvement in proteinuria was demonstrated with belimumab at Week 48 (p&#x2009;=&#x2009;0.037) and at all subsequent time points (all p&#x2009;&lt;&#x2009;0.05). Over the course of 96 weeks, belimumab treatment was associated with renal function stabilization and an increase in C3 and C4 levels. Moreover, the use of belimumab resulted in a reduction in glucocorticoid dosage at Week&#xa0;24 (p&#x2009;=&#x2009;0.02). Additionally, patients receiving belimumab treatment had a lower risk of severe treatment-emergent adverse events, and no other significant adverse effects were observed between the two groups.</AbstractText><AbstractText Label="CONCLUSIONS">In patients with LN, the utilization of belimumab therapy has demonstrated notable improvements in renal response rates. Additionally, it has shown a decreased likelihood of serious treatment-related adverse events and a diminished need for glucocorticoid dosage when compared to the active control group.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Tiening</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Operating Room, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Donghua</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Tianjin Medical University General Hospital Airport Hospital, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Youxia</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9058-0218</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Inflamm Dis</MedlineTA><NlmUniqueID>101635460</NlmUniqueID><ISSNLinking>2050-4527</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">a propensity score-matched case-control study</Keyword><Keyword MajorTopicYN="N">belimumab</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>13</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37506137</ArticleId><ArticleId IdType="pmc">PMC10373564</ArticleId><ArticleId IdType="doi">10.1002/iid3.954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barria RR. Systemic lupus erythematosus, a multidisciplinary disease. Andes Pediatr. 2021;92:337&#x2010;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">34479237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878&#x2010;1888.</Citation><ArticleIdList><ArticleId IdType="pubmed">24881804</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh MF, Jordan N, D'Cruz DP. Systemic lupus erythematosus. Clin Med. 2017;17:78&#x2010;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6297589</ArticleId><ArticleId IdType="pubmed">28148586</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology. 2020;59:v39&#x2010;v51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751166</ArticleId><ArticleId IdType="pubmed">33280015</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat&#xa0;Rev&#xa0;Nephrol. 2011;7:96&#x2010;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">21173789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Dasgupta A, Ward MM. Risk of end&#x2010;stage renal disease in patients with lupus nephritis, 1971&#x2010;2015: a systematic review and Bayesian meta&#x2010;analysis. Arthritis Rheum. 2016;68:1432&#x2010;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5071782</ArticleId><ArticleId IdType="pubmed">26815601</ArticleId></ArticleIdList></Reference><Reference><Citation>Goo YS, Park HC, Choi HY, et al. The evolution of lupus activity among patients with end&#x2010;stage renal disease secondary to lupus nephritis. Yonsei Med J. 2004;45:199&#x2010;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">15118989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bargman JM. How did cyclophosphamide become the drug of choice for lupus nephritis? Nephrol Dial Transplant. 2008;24:381&#x2010;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056783</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162:18&#x2010;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25383558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6:CD002922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513226</ArticleId><ArticleId IdType="pubmed">29957821</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215&#x2010;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell&#x2010;targeting agents. Front Med. 2020;7:303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7338653</ArticleId><ArticleId IdType="pubmed">32695790</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair HA, Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018;78:355&#x2010;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">29396833</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2:010668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095005</ArticleId><ArticleId IdType="pubmed">33631841</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty&#x2010;two&#x2010;week randomized, double&#x2010;blind, placebo&#x2010;controlled study. Arthritis Rheum. 2017;69:1016&#x2010;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434872</ArticleId><ArticleId IdType="pubmed">28118533</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo&#x2010;controlled, phase 3 trial. Lancet. 2011;377:721&#x2010;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo&#x2010;controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918&#x2010;3930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta&#x2010;Analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley M, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22:63&#x2010;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">23263865</ArticleId></ArticleIdList></Reference><Reference><Citation>Atisha&#x2010;Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheum. 2021;73:121&#x2010;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7839443</ArticleId><ArticleId IdType="pubmed">32755035</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. Two&#x2010;year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117&#x2010;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurita Gavilanes L, Costa Valarezo A. Rituximab en nefritis l&#xfa;pica: una revisi&#xf3;n no sistem&#xe1;tica. Reumatol&#xa0;Cl&#xed;n. 2016;12:210&#x2010;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">26906063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenkranz AR, Tesar V. Lupus nephritis and ANCA&#x2010;associated vasculitis: towards precision medicine? Nephrol Dial Transplant. 2021;36:37&#x2010;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">34153980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Song GG. Comparative efficacy and safety of biological agents in the treatment of lupus nephritis: a network meta&#x2010;analysis. Pharmacology. 2023;108:17&#x2010;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9843543</ArticleId><ArticleId IdType="pubmed">36327917</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha S, Budhathoki P, Adhikari Y, et al. Belimumab in lupus nephritis: a systematic review and meta&#x2010;analysis. Cureus. 2021;13:e20440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8760003</ArticleId><ArticleId IdType="pubmed">35047277</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus. Expert Opin Drug Saf. 2019;18:1133&#x2010;1144.</Citation><ArticleIdList><ArticleId IdType="pubmed">31657965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneeland R, Montes D, Endo J, Shields B, Bartels CM, Garg S. Improvement in cutaneous lupus erythematosus after twenty weeks of belimumab use: a &#xa0;review and meta&#x2010;analysis. Arthritis Care Res. 2022;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">36358025</ArticleId></ArticleIdList></Reference><Reference><Citation>Floris A, Chessa E, Sebastiani GD, et al. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real&#x2010;world GULP prospective observational study. RMD Open. 2022;8:e002701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9806067</ArticleId><ArticleId IdType="pubmed">36581383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>